| __timestamp | Soleno Therapeutics, Inc. | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2917513 | 1244910 |
| Thursday, January 1, 2015 | 7878291 | 5029636 |
| Friday, January 1, 2016 | 8366794 | 4846776 |
| Sunday, January 1, 2017 | 6610381 | 5329003 |
| Monday, January 1, 2018 | 6556000 | 7121000 |
| Tuesday, January 1, 2019 | 6930000 | 9128000 |
| Wednesday, January 1, 2020 | 8758000 | 10731000 |
| Friday, January 1, 2021 | 10806000 | 10701000 |
| Saturday, January 1, 2022 | 9844000 | 16121000 |
| Sunday, January 1, 2023 | 13481000 | 37021000 |
Cracking the code
In the competitive landscape of biotechnology, effective cost management is crucial. Over the past decade, Viking Therapeutics, Inc. and Soleno Therapeutics, Inc. have demonstrated distinct strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Viking Therapeutics saw a staggering 2,870% increase in SG&A expenses, peaking at $37 million in 2023. This reflects their aggressive expansion and investment in growth. In contrast, Soleno Therapeutics experienced a more modest 360% rise, reaching $13 million in the same year. This suggests a more conservative approach, possibly focusing on sustainable growth. The data highlights the diverse strategies within the biotech sector, where companies balance between innovation and financial prudence. As the industry evolves, these insights offer a glimpse into the financial dynamics shaping the future of biotechnology.
Who Optimizes SG&A Costs Better? Sanofi or Viking Therapeutics, Inc.
Sanofi vs Soleno Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and Viking Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Soleno Therapeutics, Inc.
Incyte Corporation and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Soleno Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Viking Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and CRISPR Therapeutics AG
SG&A Efficiency Analysis: Comparing Viking Therapeutics, Inc. and MorphoSys AG
Viking Therapeutics, Inc. and Evotec SE: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Soleno Therapeutics, Inc. vs MannKind Corporation
Selling, General, and Administrative Costs: Soleno Therapeutics, Inc. vs Xencor, Inc.